vs
Side-by-side financial comparison of Lemonade, Inc. (LMND) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Lemonade, Inc. is the larger business by last-quarter revenue ($228.1M vs $177.4M, roughly 1.3× Pacira BioSciences, Inc.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -9.5%, a 11.2% gap on every dollar of revenue. On growth, Lemonade, Inc. posted the faster year-over-year revenue change (53.3% vs 5.0%). Over the past eight quarters, Lemonade, Inc.'s revenue compounded faster (38.4% CAGR vs -0.2%).
Lemonade, Inc. is an American insurance company. The company offers renters' insurance, homeowners' insurance, car insurance, pet insurance, and term life insurance in the United States, as well as contents and liability policies in Germany and the Netherlands and renters' insurance in France. The company is based in New York City and has approximately 2.9 million customers. Lemonade does not hire human employees to process claims for customers, instead using artificial intelligence and chatb...
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
LMND vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $228.1M | $177.4M |
| Net Profit | $-21.7M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | -9.0% | 3.9% |
| Net Margin | -9.5% | 1.6% |
| Revenue YoY | 53.3% | 5.0% |
| Net Profit YoY | 27.7% | — |
| EPS (diluted) | $-0.27 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $228.1M | $196.9M | ||
| Q3 25 | $194.5M | $179.5M | ||
| Q2 25 | $164.1M | $181.1M | ||
| Q1 25 | $151.2M | $168.9M | ||
| Q4 24 | $148.8M | $187.3M | ||
| Q3 24 | $136.6M | $168.6M | ||
| Q2 24 | $122.0M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-21.7M | — | ||
| Q3 25 | $-37.5M | $5.4M | ||
| Q2 25 | $-43.9M | $-4.8M | ||
| Q1 25 | $-62.4M | $4.8M | ||
| Q4 24 | $-30.0M | — | ||
| Q3 24 | $-67.7M | $-143.5M | ||
| Q2 24 | $-57.2M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -9.0% | 1.2% | ||
| Q3 25 | -18.7% | 3.5% | ||
| Q2 25 | -26.0% | 4.7% | ||
| Q1 25 | -40.6% | 1.2% | ||
| Q4 24 | -25.4% | 13.2% | ||
| Q3 24 | -48.2% | -82.8% | ||
| Q2 24 | -45.2% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -9.5% | — | ||
| Q3 25 | -19.3% | 3.0% | ||
| Q2 25 | -26.8% | -2.7% | ||
| Q1 25 | -41.3% | 2.8% | ||
| Q4 24 | -20.2% | — | ||
| Q3 24 | -49.6% | -85.1% | ||
| Q2 24 | -46.9% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.27 | $0.05 | ||
| Q3 25 | $-0.51 | $0.12 | ||
| Q2 25 | $-0.60 | $-0.11 | ||
| Q1 25 | $-0.86 | $0.10 | ||
| Q4 24 | $-0.42 | $0.38 | ||
| Q3 24 | $-0.95 | $-3.11 | ||
| Q2 24 | $-0.81 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $399.1M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $533.6M | $653.9M |
| Total Assets | $1.9B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $399.1M | $238.4M | ||
| Q3 25 | $369.4M | $246.3M | ||
| Q2 25 | $398.8M | $445.9M | ||
| Q1 25 | $329.7M | $493.6M | ||
| Q4 24 | $403.5M | $484.6M | ||
| Q3 24 | $360.9M | $453.8M | ||
| Q2 24 | $387.2M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $533.6M | $693.1M | ||
| Q3 25 | $516.2M | $727.2M | ||
| Q2 25 | $527.1M | $757.8M | ||
| Q1 25 | $545.5M | $798.5M | ||
| Q4 24 | $593.4M | $778.3M | ||
| Q3 24 | $593.0M | $749.6M | ||
| Q2 24 | $635.2M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $1.9B | $1.3B | ||
| Q3 25 | $1.9B | $1.3B | ||
| Q2 25 | $1.9B | $1.5B | ||
| Q1 25 | $1.9B | $1.6B | ||
| Q4 24 | $1.8B | $1.6B | ||
| Q3 24 | $1.8B | $1.5B | ||
| Q2 24 | $1.7B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-16.5M | — |
| Free Cash FlowOCF − Capex | $-25.9M | — |
| FCF MarginFCF / Revenue | -11.4% | — |
| Capex IntensityCapex / Revenue | 4.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-69.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-16.5M | $43.7M | ||
| Q3 25 | $4.5M | $60.8M | ||
| Q2 25 | $5.5M | $12.0M | ||
| Q1 25 | $-47.2M | $35.5M | ||
| Q4 24 | $-11.4M | $33.1M | ||
| Q3 24 | $16.3M | $53.9M | ||
| Q2 24 | $-11.7M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-25.9M | $43.5M | ||
| Q3 25 | $2.6M | $57.0M | ||
| Q2 25 | $3.4M | $9.3M | ||
| Q1 25 | $-49.5M | $26.9M | ||
| Q4 24 | $-20.8M | $31.0M | ||
| Q3 24 | $14.1M | $49.8M | ||
| Q2 24 | $-13.2M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | -11.4% | 22.1% | ||
| Q3 25 | 1.3% | 31.7% | ||
| Q2 25 | 2.1% | 5.1% | ||
| Q1 25 | -32.7% | 15.9% | ||
| Q4 24 | -14.0% | 16.6% | ||
| Q3 24 | 10.3% | 29.6% | ||
| Q2 24 | -10.8% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 4.1% | 0.1% | ||
| Q3 25 | 1.0% | 2.2% | ||
| Q2 25 | 1.3% | 1.5% | ||
| Q1 25 | 1.5% | 5.1% | ||
| Q4 24 | 6.3% | 1.1% | ||
| Q3 24 | 1.6% | 2.4% | ||
| Q2 24 | 1.2% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LMND
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
